HC Wainwright Comments on Arvinas' Q3 Earnings (NASDAQ:ARVN)

Key Points

• HC Wainwright has lowered its Q3 2025 earnings estimate for Arvinas, now forecasting a loss of ($0.82) per share, down from a prior estimate of ($0.53), while maintaining a "Buy" rating and a price target of $18.00.
• Arvinas reported a revenue of $22.40 million for the last quarter, significantly below analyst expectations of $34.42 million, reflecting a 70.7% year-over-year decline in revenue.
• While the stock has had a consensus rating of "Moderate Buy," recent evaluations saw Citigroup, Leerink Partners, and BMO Capital Markets adjusting their price targets downward, indicating a cautious outlook from analysts.

Arvinas, Inc. (NASDAQ:ARVN - Free Report) - Research analysts at HC Wainwright reduced their Q3 2025 earnings per share (EPS) estimates for shares of Arvinas in a report released on Thursday, August 7th. HC Wainwright analyst A. Fein now expects that the company will post earnings of ($0.82) per share for the quarter, down from their previous estimate of ($0.53). HC Wainwright has a "Buy" rating and a $18.00 price objective on the stock. The consensus estimate for Arvinas' current full-year earnings is ($3.81) per share. HC Wainwright also issued estimates for Arvinas' Q4 2025 earnings at ($0.83) EPS, FY2025 earnings at ($1.36) EPS, FY2026 earnings at ($3.06) EPS, FY2027 earnings at ($2.71) EPS, FY2028 earnings at $1.83 EPS and FY2029 earnings at $0.89 EPS.

Several other equities analysts have also recently commented on the stock. Leerink Partnrs cut shares of Arvinas from a "strong-buy" rating to a "hold" rating in a research report on Sunday, June 1st. Leerink Partners reiterated a "market perform" rating and set a $9.00 price objective (down from $10.00) on shares of Arvinas in a research report on Monday, June 2nd. Piper Sandler reaffirmed an "overweight" rating and issued a $14.00 price objective (down previously from $24.00) on shares of Arvinas in a research note on Friday, May 2nd. Citigroup dropped their price objective on shares of Arvinas from $10.00 to $9.50 and set a "neutral" rating on the stock in a report on Monday, May 5th. Finally, BTIG Research set a $16.00 target price on shares of Arvinas and gave the company a "buy" rating in a research note on Friday, May 2nd. Ten analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $19.76.

Arvinas Stock Down 3.0%

Shares of Arvinas stock traded down $0.22 during trading hours on Monday, hitting $6.87. 327,632 shares of the company's stock traded hands, compared to its average volume of 2,187,978. The stock has a 50 day simple moving average of $7.51 and a 200-day simple moving average of $9.74. The company has a market cap of $504.69 million, a PE ratio of -6.79 and a beta of 2.22. Arvinas has a twelve month low of $5.90 and a twelve month high of $29.61.

Arvinas (NASDAQ:ARVN - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.84) earnings per share for the quarter, topping analysts' consensus estimates of ($0.87) by $0.03. The company had revenue of $22.40 million for the quarter, compared to analyst estimates of $34.42 million. Arvinas had a negative return on equity of 12.01% and a negative net margin of 19.47%. The business's revenue for the quarter was down 70.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.49) EPS.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Invesco Ltd. raised its stake in Arvinas by 1.6% in the fourth quarter. Invesco Ltd. now owns 37,254 shares of the company's stock valued at $714,000 after purchasing an additional 581 shares in the last quarter. Bank of Montreal Can raised its stake in Arvinas by 2.7% in the fourth quarter. Bank of Montreal Can now owns 39,407 shares of the company's stock valued at $755,000 after purchasing an additional 1,044 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Arvinas by 3.8% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 36,514 shares of the company's stock valued at $700,000 after purchasing an additional 1,353 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in Arvinas in the fourth quarter valued at approximately $28,000. Finally, LPL Financial LLC raised its stake in Arvinas by 12.5% in the fourth quarter. LPL Financial LLC now owns 18,669 shares of the company's stock valued at $358,000 after purchasing an additional 2,077 shares in the last quarter. Institutional investors and hedge funds own 95.19% of the company's stock.

Insider Buying and Selling

In related news, CFO Andrew Saik sold 5,700 shares of Arvinas stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $7.61, for a total transaction of $43,377.00. Following the sale, the chief financial officer directly owned 164,401 shares of the company's stock, valued at approximately $1,251,091.61. The trade was a 3.35% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 4.73% of the company's stock.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.